Exchange: NASDAQ·Updated 05:37 AM EDT
News
all
press releases
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -28.57% and -59.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?
A potential AstraZeneca-Bristol Myers deal worth $400 billion would create one of the world’s largest drugmakers and combine major cancer franchises.
Stocktwits
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
Zacks
The New Cancer Moonshot: Innovative Companies Pursuing Game-Changing Therapies
Cancer treatment is undergoing one of the most significant transformations in modern medical history.
24-7 Market News
RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst
RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst...
Yahoo! Finance: News
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -23.33% and +80.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of +7.68% and +0.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet
The consensus price target hints at a 29.8% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
Here is how Brainsway Ltd. Sponsored ADR (BWAY) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.
Zacks
CG Oncology, Inc. (CGON) Upgraded to Buy: Here's What You Should Know
CG Oncology, Inc. (CGON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks

Advertisement|Remove ads.